Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD.

ABSTRACT: Introduction: Chronic inflammation is the core mechanism of the development of chronic obstructive pulmonary disease (COPD). Corticosteroid resistance in COPD limits its anti-inflammatory potency. p38 MAPKIs were suggested as an alternative to corticosteroids despite the fact that there is currently no systematic review evaluating existing evidence. Methods: This randomized controlled trials (RCT)-based systematic review with meta-analysis was conducted following the PRISMA statement. RCTs were searched and screened from 8 databases. Three types of data, including basic information of included studies, pre-defined outcome data, and quality assessment information were extracted. Pooling values and associated 95 % confidence intervals were deemed as statistically significant on

SUBMITTER: Yu H 

PROVIDER: S-EPMC9554617 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature